IBM Explores Sale of IBM Watson Health
18 Fevereiro 2021 - 10:36PM
Dow Jones News
By Laura Cooper and Cara Lombardo
International Business Machines Corp. is exploring a potential
sale of its IBM Watson Health business, according to people
familiar with the matter, as the technology giant's new chief
executive moves to streamline the company and become more
competitive in cloud computing.
IBM is studying alternatives for the unit that could include a
sale to a private-equity firm or industry player or a merger with a
blank-check company, the people said. The unit, which employs
artificial intelligence to help hospitals, insurers and drugmakers
manage their data, has roughly $1 billion in annual revenue and
isn't currently profitable, the people said.
Its brands include Merge Healthcare, which analyzes mammograms
and MRIs; Phytel, which assists with patient communications; and
Truven Health Analytics, which analyzes complex healthcare
data.
It isn't clear how much the business might fetch in a sale, and
there may not be one.
Write to Laura Cooper at laura.cooper@wsj.com and Cara Lombardo
at cara.lombardo@wsj.com
(END) Dow Jones Newswires
February 18, 2021 20:21 ET (01:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
International Business M... (NYSE:IBM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
International Business M... (NYSE:IBM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024